Jacobio Pharmaceuticals Group (HKG:1167) narrowed its attributable loss to 59 million yuan in the first half of 2025 from 169.1 million yuan a year prior, an Aug. 29 Hong Kong bourse filing said.
Shares of the pharmaceutical company were up 23% at close of trade.
Loss per share was 0.08 yuan, down from 0.22 yuan in the year-ago period.
Revenue for the interim period rose to 45.7 million yuan, compared with no revenue in the prior year, due to a milestone payment under the Allist licensing agreement.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.